SG134170A1 - Method of treating of demyelinating diseases or conditions - Google Patents

Method of treating of demyelinating diseases or conditions

Info

Publication number
SG134170A1
SG134170A1 SG200505802-9A SG2005058029A SG134170A1 SG 134170 A1 SG134170 A1 SG 134170A1 SG 2005058029 A SG2005058029 A SG 2005058029A SG 134170 A1 SG134170 A1 SG 134170A1
Authority
SG
Singapore
Prior art keywords
treatment
conditions
demyelinating diseases
treating
compounds
Prior art date
Application number
SG200505802-9A
Other languages
English (en)
Inventor
Craig P Smith
Michel P Rathbone
Margaret Petty
David Rampe
Original Assignee
Aventis Pharma Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Aventis Pharma Inc filed Critical Aventis Pharma Inc
Publication of SG134170A1 publication Critical patent/SG134170A1/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
    • A61K31/4439—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. omeprazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/02—Drugs for disorders of the urinary system of urine or of the urinary tract, e.g. urine acidifiers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/10—Drugs for disorders of the urinary system of the bladder
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/02—Drugs for disorders of the nervous system for peripheral neuropathies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/04—Centrally acting analgesics, e.g. opioids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis

Landscapes

  • Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Biomedical Technology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Urology & Nephrology (AREA)
  • Epidemiology (AREA)
  • Rheumatology (AREA)
  • Pain & Pain Management (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Immunology (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Obesity (AREA)
  • Diabetes (AREA)
  • Psychiatry (AREA)
  • Ophthalmology & Optometry (AREA)
  • Vascular Medicine (AREA)
  • Hematology (AREA)
  • Dermatology (AREA)
  • Hospice & Palliative Care (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Indole Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
SG200505802-9A 2001-02-15 2002-02-14 Method of treating of demyelinating diseases or conditions SG134170A1 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US26884601P 2001-02-15 2001-02-15
GBGB0119435.6A GB0119435D0 (en) 2001-02-15 2001-08-09 Method of treating of demyelinating diseases or conditions

Publications (1)

Publication Number Publication Date
SG134170A1 true SG134170A1 (en) 2007-08-29

Family

ID=23024747

Family Applications (1)

Application Number Title Priority Date Filing Date
SG200505802-9A SG134170A1 (en) 2001-02-15 2002-02-14 Method of treating of demyelinating diseases or conditions

Country Status (39)

Country Link
US (10) US6967210B2 (fr)
EP (1) EP1368031A2 (fr)
JP (3) JP2004518711A (fr)
KR (3) KR100951542B1 (fr)
CN (2) CN1529598A (fr)
AP (1) AP1749A (fr)
AR (1) AR035750A1 (fr)
AU (3) AU2002247200B9 (fr)
BR (1) BR0207272A (fr)
CA (1) CA2438712A1 (fr)
CO (1) CO5390085A1 (fr)
CR (1) CR7023A (fr)
CZ (1) CZ20032172A3 (fr)
EA (2) EA012409B1 (fr)
EC (1) ECSP024218A (fr)
EE (1) EE200300363A (fr)
GB (1) GB0119435D0 (fr)
HK (1) HK1080361B (fr)
HR (1) HRP20030652A2 (fr)
HU (1) HUP0303203A3 (fr)
IL (2) IL157341A0 (fr)
MA (1) MA26152A1 (fr)
ME (1) MEP21208A (fr)
MX (1) MXPA03006110A (fr)
MY (1) MY157745A (fr)
NO (1) NO20033622L (fr)
NZ (4) NZ544720A (fr)
OA (1) OA12549A (fr)
PA (1) PA8540101A1 (fr)
PE (1) PE20040175A1 (fr)
PL (1) PL363638A1 (fr)
SG (1) SG134170A1 (fr)
SK (1) SK10392003A3 (fr)
TR (4) TR200800693T2 (fr)
TW (1) TWI325319B (fr)
UA (2) UA80394C2 (fr)
WO (1) WO2002064126A2 (fr)
YU (1) YU62903A (fr)
ZA (1) ZA200306124B (fr)

Families Citing this family (17)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB0119435D0 (en) * 2001-02-15 2001-10-03 Aventis Pharm Prod Inc Method of treating of demyelinating diseases or conditions
JP2006511624A (ja) * 2002-12-20 2006-04-06 ダイノジェン ファーマシューティカルズ， インコーポレイテッド α２δサブユニット・カルシウム・チャンネル調節因子を使用する無痛性膀胱障害を処置するための方法
WO2004066990A2 (fr) * 2003-01-30 2004-08-12 Dynogen Pharmaceuticals, Inc. Methodes destinees a traiter les troubles du tractus urinaire inferieur au moyen de modulateurs du canal sodique
ES2275229T3 (es) * 2003-03-21 2007-06-01 Dynogen Pharmaceuticals, Inc. Metodos para el tratamiento de desordenes del tracto urinario iferior utilizando antimuscarinos y moduladores de la subunidad alfa-2-delta del canal de calcio.
GT200500063A (es) * 2004-04-01 2005-10-14 Metodo para tratar la esquizofrenia y/o anormalidades glucoregulatorias
GB0510164D0 (en) * 2005-04-28 2005-06-22 Paradigm Therapeutics Ltd Ion channel
FR2892021B1 (fr) * 2005-10-19 2008-01-04 Urogene Traitement de l'incontinence urinaire d'effort et mixte
FR2892022B1 (fr) * 2005-10-19 2008-01-04 Urogene Sa Traitement des symptomes de l'irritation de la vessie
US8420593B1 (en) * 2006-06-16 2013-04-16 Landon C. G. Miller Compositions and methods for regulating membrane potential
DE102008044844B4 (de) * 2008-08-28 2018-08-30 Siemens Healthcare Gmbh Verfahren zur Ermittlung einer Schwächungskarte zur Verwendung in der Positronenemissionstomographie und von Homogenitätsinformationen des Magnetresonanzmagnetfeldes
CN102822979B (zh) * 2010-03-26 2015-08-26 株式会社半导体能源研究所 半导体器件
US20130184316A1 (en) * 2010-07-15 2013-07-18 Andrew Hornstein Methods for diagnosing and treating concussive disorders
BR112013019265A2 (pt) * 2011-01-28 2016-10-11 Acorda Therapeutics Inc uso de bloqueadores do canal de potássio no tratamento da paralisia cerebral
TWI592156B (zh) * 2011-10-04 2017-07-21 艾可達醫療公司 使用胺基吡啶以治療與中風有關之感覺動作損傷之方法
WO2017151409A1 (fr) 2016-02-29 2017-09-08 University Of Florida Research Foundation, Incorporated Méthodes de chimiothérapie
EP3727587A4 (fr) * 2017-12-22 2022-02-23 Massachusetts Institute Of Technology Compositions et méthodes de thérapie du syndrome de williams (sw)
CA3207205A1 (fr) * 2021-01-20 2022-07-28 Rush University Medical Center Traitement ameliore pour la leucodsytrophie a cellules globoides ou la maladie de krabbe

Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4970218A (en) * 1987-04-24 1990-11-13 Hoechst-Roussel Pharmaceuticals Inc. N-(pyridinyl)-1H-indol-1-amines
EP0287982B1 (fr) * 1987-04-24 1994-12-07 Hoechst-Roussel Pharmaceuticals Incorporated N-(pyridinyl)-1H-indol-1-amines, leur procédé de préparation et leur utilisation comme médicaments
EP0415103B1 (fr) * 1989-08-02 1995-02-01 Hoechst-Roussel Pharmaceuticals Incorporated 2,3-Dihydro-1-(pyridinylamino)-indoles, procédé pour leur préparation et leur utilisation comme médicaments
EP0683165B1 (fr) * 1994-05-13 2000-08-02 Aventis Pharmaceuticals Inc. Procédé pour la préparation de N-alkyl-N-pyridinyl-1H-indol-1-amines

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4880822A (en) * 1987-04-24 1989-11-14 Hoechst-Roussel Pharmaceuticals, Inc. N-(pyridinyl)-1H-indol-1-amines
US5214038A (en) * 1991-04-15 1993-05-25 Hoechst-Roussel Pharmaceuticals Inc. 1-(pyrido[3,4-b]-1,4-oxazinyl-4-yl)-1H-indoles and intermediates for the preparation thereof
DE4325491A1 (de) * 1993-07-29 1995-02-02 Boehringer Ingelheim Kg Verwendung von zentral wirksamen alpha-2-Agonisten zur Hemmung des Postaggressionsstoffwechsels
US5565475A (en) * 1994-11-08 1996-10-15 Muhlhauser; Mark A. Method of treating urinary bladder dysfunctions with 3-tetrahydropyridine derivatives
EP0731108A1 (fr) * 1995-03-10 1996-09-11 Boehringer Mannheim Gmbh Procédé de fabrication d'un agent thérapeutique pour la régénération d'oligodendrocytes
FR2754147B1 (fr) 1996-10-03 2000-02-04 Mbh Technologies Sa Installation et procede pour le traitement de carcasses
ATE252590T1 (de) * 1998-01-29 2003-11-15 Bristol Myers Squibb Co Phosphorylierte derivate des diaryl 1,3,4 oxadiazolon
AU5483500A (en) * 1999-07-09 2001-01-30 Ortho-Mcneil Pharmaceutical, Inc. Neurotrophic 2-azetidinecarboxylic acid derivatives, and related compositions and methods
GB0119435D0 (en) * 2001-02-15 2001-10-03 Aventis Pharm Prod Inc Method of treating of demyelinating diseases or conditions

Patent Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4970218A (en) * 1987-04-24 1990-11-13 Hoechst-Roussel Pharmaceuticals Inc. N-(pyridinyl)-1H-indol-1-amines
EP0287982B1 (fr) * 1987-04-24 1994-12-07 Hoechst-Roussel Pharmaceuticals Incorporated N-(pyridinyl)-1H-indol-1-amines, leur procédé de préparation et leur utilisation comme médicaments
EP0415103B1 (fr) * 1989-08-02 1995-02-01 Hoechst-Roussel Pharmaceuticals Incorporated 2,3-Dihydro-1-(pyridinylamino)-indoles, procédé pour leur préparation et leur utilisation comme médicaments
EP0683165B1 (fr) * 1994-05-13 2000-08-02 Aventis Pharmaceuticals Inc. Procédé pour la préparation de N-alkyl-N-pyridinyl-1H-indol-1-amines

Non-Patent Citations (2)

* Cited by examiner, † Cited by third party
Title
4-AMINOPYRIDINE DERIVATIVES: A FAMILY OF NOVEL MODULUTORS OF VOLTAGE-DEPENDENT SODIUM CHANNELS *
MUSCARINIC RECEPTOR LIGANDS AND THEIR THERAPEUTIC POTENTIAL *

Also Published As

Publication number Publication date
AU2002247200B2 (en) 2007-12-13
HK1080361A1 (en) 2006-04-28
US7534803B2 (en) 2009-05-19
TR200800691T2 (tr) 2008-03-21
PA8540101A1 (es) 2003-09-05
AU2002247200B9 (en) 2008-07-10
HUP0303203A3 (en) 2007-11-28
EP1368031A2 (fr) 2003-12-10
JP2009185045A (ja) 2009-08-20
EA200600896A1 (ru) 2006-08-25
US20090209594A1 (en) 2009-08-20
BR0207272A (pt) 2004-02-10
TR200301330T2 (tr) 2004-12-21
PE20040175A1 (es) 2004-03-29
US20090270458A1 (en) 2009-10-29
YU62903A (sh) 2006-05-25
US20050159456A1 (en) 2005-07-21
AP1749A (en) 2007-06-13
US7230015B2 (en) 2007-06-12
EA200300882A1 (ru) 2003-12-25
OA12549A (en) 2006-06-05
MY157745A (en) 2016-07-15
TR200800692T2 (tr) 2008-03-21
WO2002064126A3 (fr) 2003-02-20
US20040157889A1 (en) 2004-08-12
US20040157888A1 (en) 2004-08-12
CO5390085A1 (es) 2004-04-30
KR100951540B1 (ko) 2010-04-09
SK10392003A3 (sk) 2004-01-08
TWI325319B (en) 2010-06-01
US20090281147A1 (en) 2009-11-12
NO20033622D0 (no) 2003-08-14
AP2003002834A0 (en) 2003-09-30
PL363638A1 (en) 2004-11-29
AU2008201179A1 (en) 2008-04-03
JP2010120958A (ja) 2010-06-03
CN1529598A (zh) 2004-09-15
UA88773C2 (ru) 2009-11-25
IL157341A0 (en) 2004-02-19
MA26152A1 (fr) 2004-07-01
UA80394C2 (en) 2007-09-25
KR20040014459A (ko) 2004-02-14
IL157341A (en) 2010-11-30
NZ539159A (en) 2006-11-30
US7179821B2 (en) 2007-02-20
MEP21208A (en) 2010-06-10
US6967210B2 (en) 2005-11-22
ZA200306124B (en) 2004-11-08
CN100522164C (zh) 2009-08-05
NZ527011A (en) 2005-07-29
AR035750A1 (es) 2004-07-07
EA011319B1 (ru) 2009-02-27
AU2009238332A1 (en) 2009-12-10
HK1080361B (zh) 2009-10-30
NO20033622L (no) 2003-10-06
ECSP024218A (es) 2003-09-24
KR20090005255A (ko) 2009-01-12
KR100951542B1 (ko) 2010-04-09
CN1679564A (zh) 2005-10-12
JP2004518711A (ja) 2004-06-24
KR20090005254A (ko) 2009-01-12
HUP0303203A2 (hu) 2003-12-29
GB0119435D0 (en) 2001-10-03
CZ20032172A3 (cs) 2004-01-14
AU2008201179B2 (en) 2009-08-20
NZ556697A (en) 2009-01-31
US20050234105A1 (en) 2005-10-20
HRP20030652A2 (en) 2005-06-30
US20030105150A1 (en) 2003-06-05
CR7023A (es) 2003-11-17
EE200300363A (et) 2003-10-15
CA2438712A1 (fr) 2002-08-22
US20090209595A1 (en) 2009-08-20
WO2002064126A2 (fr) 2002-08-22
MXPA03006110A (es) 2005-07-01
EA012409B1 (ru) 2009-10-30
TR200800693T2 (tr) 2008-07-21
NZ544720A (en) 2007-08-31
US20060025452A1 (en) 2006-02-02

Similar Documents

Publication Publication Date Title
AP1749A (en) Method of treating of demyelinating diseases or conditions.
PL374865A1 (en) Treatment of tnf alpha related disorders
GB0225475D0 (en) Therapeutic agents
IL157320A0 (en) Rapid-onset medicament for the treatment of sexual dysfunction
EP1420854A4 (fr) Traitement de troubles neuropsychiatriques par stimulation nerveuse a proximite du diaphragme
AU5584901A (en) Use of cyclic gmp-specific phosphodiesterase inhibitors for treatment of parkinson's disease
WO2004019863A3 (fr) Therapie de combinaison pour le traitement de troubles fibrosants
WO2007127475A3 (fr) Compositions et traitements contre des maladies démyélinisantes et des troubles de type douleur
AU3831301A (en) Method for treating ocular pain
AU2003300791A1 (en) Combination therapy for the treatment of pain
EP1251126A3 (fr) Derives de benzenesulfonyle a substitution fluor pour le traitment d'inflammation
HK1075843A1 (en) 1-phenyl-2-dimethylaminomethyl cyclohexane compounds used for the therapy of depressive symptoms, pain, and incontinence
SI1532131T1 (sl) Motilidne spojine
WO2004093807A3 (fr) Vecteurs de somatostatine
MXPA02001204A (es) Compuestos calciliticos.
BG103252A (en) The use of benzopyranols for the treatment of neurological disorders
AU2003255843A1 (en) 1,3-thiazolin-4-ones as therapeutic compounds in the treatment of pain
MXPA05006722A (es) Metodo para tratamiento de pacientes con exposicion a radiacion.
WO2003020221A3 (fr) Methode de traitement d'une maladie cancereuse
WO2002089848A3 (fr) Methode de traitement du diabete
AU2001276323A1 (en) Use of n-oleoylethanolamine for treating psoriasis
UY27206A1 (es) Método de tratamiento de condiciones o enfermedades desmielinizantes
TH60984A (th) วิธีรักษาโรค หรือสภาวะจากการสูญเสียไมอีลิน
WO2001089510A3 (fr) Methode de traitement de l'obesite
UA33498A (uk) Спосіб лікування терапевтично резистентних форм шизофренії